Clinical Trials Browser

Lung Neoplasms × aflutinib × 1 year × Clear all

NCT07185997 2026-05-11

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Phase 2 Not yet recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant